ClinicalTrials.gg
CompletedNCT07014644Updated Jun 11, 2025

A Randomized, Double-Blind, Single-Center Clinical Study on the Efficacy of Naltrexone Implant in Antagonizing Opioid Agonist Hydromorphone

A Phase 2 interventional study of 0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo and 1.5g Naltrexone Implant in Opioid Dependence, sponsored by Shenzhen Sciencare Medical Industries Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Shenzhen Sciencare Medical Industries Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 9 months after the study started (first participant enrolled Aug 2018, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies testing naltrexone in Opioid-Related Disorders — 1 open to participants now, 2 under way, none of them phase 3. Naltrexone · Opioid-Related Disorders.

Enrollment
36th of 52
31 · median 61
Started
2018
with 3 others
Phase 2
14 of 52
1 open now
Registered
52nd of 52
by date

Among the 52 studies testing naltrexone in Opioid-Related Disorders, this one is the 36th largest by enrollment, is one of 4 that started in 2018, is one of 14 in phase 2, and was the 52nd registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

1 of the 52 studies testing naltrexone in Opioid-Related Disorders is open now. Recruiting first, the newest first:

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing naltrexone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This study adopted a randomized, double-blind study design to evaluate the antagonistic effect, safety and pharmacokinetics of Naltrexone (opioid receptor antagonist) implantation after Hydromorphone (opioid receptor agonist) challenge.By using the method of multiple Hydromorphone challenge tests and assessing the clinical symptoms and signs related to opioid agonism as well as the pharmacokinetic parameters of Naltrexone and Hydromorphone, this study aimed to investigate the antagonistic effect of different doses of Naltrexone Implants post dosing in different time periods on different doses of Hydromorphone, to understand the ability of Naltrexone to antagonize Hydromorphone and its effective blood concentration, and to explore the effective dose and duration of Naltrexone Implants in antagonizing Hydromorphone. The study also aimed to provide a basis for the clinical use of Naltrexone Implants in the anti-relapse treatment of opioid dependence, and to provide a reference for the design of Phase 3 clinical studies.

03

Conditions studied

  • Opioid Dependence
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 65 years;
  2. Those who had abused opioids for more than 1 year, and had used drugs at least once aweek in the abuse history;
  3. Opioid-dependent subjects in the convalescent stage who had discontinued using opioids for more than 30 days and had a negative urine test for opioids;
  4. Weight: male ≥ 45 kg, female ≥ 40 kg;
  5. Physical condition: the subjects were screened within 2 weeks before the study, and had no medical history of heart, liver, kidney, digestive tract, nervous system, mental abnormality or metabolic abnormality; comprehensive physical examinations showed that the subjects had normal or abnormal but not , blood pressure, heart rate, respiratory status and laboratory tests including chest X-ray (results within half a year were valid), blood routine, urine routine, hepatic function, renal function, blood glucose, blood lipid, coagulation function and other biochemical tests at the discretion of the clinician;
  6. Subjects without eye disease or optic neuropathy;
  7. The subjects and their witnesses must give to this study before the study, and the subjects voluntarily signed a written informed consent;
  8. The subjects could communicate well with the investigator and complete the study in accordance with the study regulations.

Exclusion criteria

Exclusion Criteria:

  • (1) Patients with major diseases or major surgical operations within 4 weeks before the study; (2) Those with a history of heart, kidney, digestive tract and other important organs and hematopoietic system diseases; (3) Patients with bleeding tendency and leukopenia; (4) Patients with chronic pain or epilepsy; (5) Patients with serious mental and neurological diseases; (6) Patients with suicidal tendency; (7) Those who had a history of allergy to Hydromorphone or those who were allergic to Naltrexone and its ; (8) Those with blood loss or blood donation up to 200 ml within 3 months before the study; (9) Those who had participated in clinical studies of other drugs within 3 months before the study, or were participating in clinical studies of other drugs; (10) Those who had used drugs known to damage a certain organ or were currently using such drugs within 3 months before the study; (11) Those who had used prescription analgesics or psychiatric drugs within 30 days before the study; (12) Those who had used any drug that would inhibit or induce hepatic metabolism of drugs within one week before the study (e.g.: inducers - barbiturates, carbamazepine, phenytoin, , omeprazole; inhibitors - SSRI antidepressants, cimetidine, diltiazem macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines); (13) Any other surgical or medical condition that could potentially jeopardize the subject's participation in the study and alter the absorption, distribution, metabolism, and excretion of the drug, including the following:

    1. Inflammatory bowel syndrome, peptic ulcer, or gastrointestinal bleeding;
    2. History of serious gastrointestinal surgery, such as gastrectomy, gastrostomy, or colectomy;
    3. History of liver disease and hepatic function laboratory tests such as: (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase(γ-GT), or total (T-Bili) greater than 1.5 × (ULN) and judged by the clinician as abnormal and clinically significant;4) Clinically significant abnormalities in medical history or laboratory tests for creatinine, blood urea nitrogen, or urine components (e.g., proteinuria), suggesting renal impairment; (14) Those with a history of immunodeficiency, including a positive test; (15) Those who were not suitable to participate in the study at the discretion of the investigator. In addition to the above requirements, female subjects who met the following conditions should also be excluded: (16) Those who took oral 30 days before the study; (17) Those who had used within 6 months before the study and might use during the study long-acting estrogen or progestin injections or implants; (18) Women of childbearing age who had experienced unprotected sexual intercourse with their partners within 14 days before the study; (19) Women in pregnancy or lactating;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    0.9 g

    Drug: 0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo

  • Experimental
    1.5 g

    Drug: 1.5g Naltrexone Implant

Interventions

  • Drug0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo

    0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo

  • 1.5g Naltrexone Implant

06

What researchers measure

Primary outcomes

  1. Effective Antagonistic Dose of Naltrexone Implant for Opioid Antagonism

    Effective Antagonistic Dose of Naltrexone Implant for Opioid Antagonism

    Time frame: 150 day

07

Study locations

1 site
  • The Second Xiangya Hospital of Central South University Address: No. 139, Renmin Road Central, Changsha City
    Changsha, HU Nan 410011, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in May 2020, 21 months.

Of 68 phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Aug 7, 2018
Primary completionActual
May 13, 2020
CompletionActual
May 19, 2020
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07014644
Lead sponsor
Shenzhen Sciencare Medical Industries Co., Ltd.
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Aug 7, 2018
Primary completion
May 13, 2020
Completion
May 19, 2020
Last update
Jun 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion